The Effect of Vitamin D Supplementation on the Pulmonary Functions of Adult Asthmatic Egyptian Patients

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02747381

Enrollment

Registered

2016-04-21

Start date

2014-08-31

Completion date

2016-04-30

Last updated

2016-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Brief summary

This study evaluates the effect of vitamin D supplementation in the form of Alfacalcidol on the the pulmonary function of adult asthmatic Egyptian patients

Detailed description

Asthmatic patients are recruited and divided into two groups. One receives Alfacalcidol beside their normal medications while the other acts as a control group receiving the normal asthma medication. Both groups are followed up for four months.

Interventions

DIETARY_SUPPLEMENTAlfacalcidol

1-alpha hydroxy cholecalciferol 1 mcg

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

1. Patients diagnosed with asthma 2. Non-smokers

Exclusion criteria

1. Liver impairment 2. Kidney impairment 3. Patients receiving digoxin 4. Known hypersensitivity to 1α-hydroxyvitamin D3, vitamin D or any of its analogues and derivatives 5. Hypercalcaemia 6. Hyperphosphatemia 7. Pregnancy and breast-feeding 8. Patients on nutritional supplements with a potential effect on 25(OH)D serum concentrations 9. Had a History of stones in the urinary tract or diseases of calcium or bone metabolism

Design outcomes

Primary

Measure	Time frame
forced expiratory volume % predicted values	4 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026